ADMA Biologics Inc (NASDAQ:ADMA) Stock Traded -7.5% Below Its 50 Day Moving Average


Shares last traded at $2.97 which is just under $3.21, the stock’s 50 day moving average and significantly lower than the 200 day moving average of $3.56. The 50 day moving average was down $-0.24 or -7.46% and the 200 day average went down by -16.69%. (NASDAQ:ADMA) shares saw light trading volume with 111 shares changing hands by the end of trading on Tuesday. Volume was down 99.52% under the stocks average daily volume.

Investors are more bullish on shares of ADMA Biologics Inc at least if you consider the downtick in short interest. The firm recorded a fall in short interest of -16.64% between September 15, 2017 and September 29, 2017. Short shares fell from 47,245 to 39,382 over that period. Days to cover increased 1.0 to 2.0 and the percentage of shorted shares was 0.00% on September 29.

Here are a few substantial investment firms who have updated their positions. As of quarter end Weiss Multi-strategy Advisers LLC had disposed of 20,000 shares trimming its stake by 50.0%. The value of the total investment in ADMA Biologics Inc decreased from $195,000 to $74,000 decreasing 62.1% quarter to quarter. Tower Research Capital LLC (trc) grew its position by buying 622 shares an increase of 119.8% in the quarter. Tower Research Capital LLC (trc) now controls 1,141 shares worth $4,000. The total value of its holdings increased 33.3%.

As of the end of the quarter Spark Investment Management LLC had sold a total of 8,087 shares trimming its holdings by 43.0%. The value of the investment in (ADMA) went from $91,000 to $39,000 a change of $52,000 for the reporting period. Iguana Healthcare Management, LLC added to its investment by buying 50,000 shares an increase of 50.0% as of 06/30/2017. Iguana Healthcare Management, LLC currently owns 150,000 shares valued at $555,000. The value of the position overall is up by 13.7%.

As of the latest earnings report the EPS was $-1.77 and is estimated to be $-1.74 for the current year with 25,793,000 shares outstanding. Analysts expect next quarter’s EPS to be $-0.37 with next year’s EPS anticipated to be $-1.08.

ADMA Biologics, Inc., launched on June 2, 2006, is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is involved in the development and commercialization of human plasma and plasma-derived therapeutics. The Business’s segments include Plasma Collection Centers, Research and Development, and Corporate. The Plasma Collection Centers segment includes the Business’s operations in Georgia. The Research and Development segment includes the Business’s plasma development operations in New Jersey. The Business’s targeted patient populations include immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. The Business’s lead product candidate, RI-002, is intended for the treatment of primary immune deficiency disease (PIDD) and has completed a pivotal Phase III clinical study..